Kymera Therapeutics KYMR Operating Lease Liabilities (Current)
Operating Lease Liabilities (Current) at other companies
Other financials
Where this comes from
Reported directly by Kymera Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:OperatingLeaseLiabilityCurrent.
The official record: Kymera Therapeutics’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Kymera Therapeutics's operating lease liabilities (current).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Kymera Therapeutics's operating lease liabilities (current)?
- Kymera Therapeutics (KYMR) reported operating lease liabilities (current) of $12.03M in Q1 2026.
- How has Kymera Therapeutics's operating lease liabilities (current) changed year-over-year?
- Kymera Therapeutics's operating lease liabilities (current) increased by 3.0% year-over-year, from $11.68M to $12.03M.
- What is the long-term trend for Kymera Therapeutics's operating lease liabilities (current)?
- Over 5 years (2020 to 2025), Kymera Therapeutics's operating lease liabilities (current) has grown at a 35.9% compound annual growth rate (CAGR), from $2.57M to $11.94M.
- What does operating lease liabilities (current) mean?
- The current portion of operating lease obligations due within one year, representing committed future lease payments under ASC 842.